0001567619-15-001311.txt : 20150930 0001567619-15-001311.hdr.sgml : 20150930 20150930205217 ACCESSION NUMBER: 0001567619-15-001311 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20150930 DATE AS OF CHANGE: 20150930 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edge Therapeutics, Inc. CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1600 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1600 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BLECH ISAAC CENTRAL INDEX KEY: 0000905536 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 151135159 3 1 s001053x11_form3.xml FORM 3 X0206 3 2015-09-30 0 0001472091 Edge Therapeutics, Inc. EDGE 0000905536 BLECH ISAAC 200 CONNELL DRIVE, SUITE 1600 BERKELEY HEIGHTS NJ 07922 1 0 0 0 Stock Option (right to purchase) 2.39 2022-12-19 Common Stock 730940 D Stock Option (right to purchase) 2.04 2023-10-11 Common Stock 11695 D Stock Option (right to purchase) 8.28 2024-03-27 Common Stock 4385 D Stock Option (right to purchase) 11 2025-09-30 Common Stock 21928 D This option, representing a right to purchase a total of 730,940 shares of Common Stock, became exercisable on December 19, 2012 with 50% vesting on that date and the remaining 50% vesting in 16 equal quarterly installments thereafter beginning on July 31, 2013, subject to continued service as director through each vesting date. This option, representing a right to purchase a total of 11,695 shares of Common Stock, became exercisable on October 11, 2013 with 30% vesting on that date and the remaining 70% vesting in 14 equal quarterly installments thereafter, subject to continued service as director through each vesting date. This option, representing a right to purchase a total of 4,385 shares of Common Stock, became exercisable on June 1, 2013, with 25% vesting on that date and the remaining 75% vesting in 12 equal quarterly installments thereafter, subject to continued service as director through each vesting date. This option, representing a right to purchase a total of 21,928 shares of Common Stock, will become exercisable upon the earlier of the first anniversary of the date of grant or the issuer's next annual stockholders meeting, subject to continued service as director through the vesting date. /s/ Albert Marchio, attorney-in-fact 2015-09-30 EX-24.1 2 s001053x11_ex24-1.htm POWER OF ATTORNEY

Exhibit 24.1

LIMITED POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Andrew J. Einhorn and Albert N. Marchio II, as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

(1) prepare, execute on behalf of the undersigned and submit to the U.S. Securities and Exchange Commission (the “SEC”), with respect to the securities of Edge Therapeutics Inc., a Delaware corporation (the “Company”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 13 and Section 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) or any rule or regulation of the SEC;

(2) execute for and on behalf of the undersigned, with respect to the securities of the Company, any required (i) Schedules 13D and 13G in accordance with Section 13 of the Exchange Act and the rules thereunder, (ii) Forms 3, 4 and 5 in accordance with Section 16(a) of the Exchange Act and the rules thereunder, and (iii) Form 144 under Rule 144 of the Securities Act of 1933;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D or 13G, Form 3, 4, 5, or 144 and complete and execute any amendment or amendments thereto, and timely file any such form with the SEC and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, hereby ratifying and confirming all that such attorney-in-fact shall lawfully do or cause or have caused to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at [his/her] request, are not assuming any of the undersigned’s responsibilities to comply with Section 13 and 16 of the Securities Exchange Act of 1934 and Rule 144 of the Securities Act of 1933.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Schedules 13D and 13G, and Forms 3, 4, 5 and 144 with respect to the securities of the Company held by the undersigned, unless earlier revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

[signature page follows]

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 30^th day of September, 2015.

By: /s/ Isaac Blech

Name: Isaac Blech